메뉴 건너뛰기




Volumn 8, Issue 1, 2003, Pages 23-25

Unknown primary carcinoma: A feasibility assessment of combination chemotherapy with cisplatin and docetaxel

Author keywords

Docetaxel; Pilot study; Unknown primary carcinoma

Indexed keywords

CISPLATIN; DOCETAXEL;

EID: 0037296547     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470300002     Document Type: Article
Times cited : (10)

References (14)
  • 1
    • 0028241857 scopus 로고
    • Unknown primary carcinoma: Natural history and prognostic factors in 657 consecutive patients
    • Abbruzzese JL, Abbruzzese MC, Hess KR, et al. (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12:1272-1280
    • (1994) J Clin Oncol , vol.12 , pp. 1272-1280
    • Abbruzzese, J.L.1    Abbruzzese, M.C.2    Hess, K.R.3
  • 2
    • 0017336436 scopus 로고
    • Metastatic and histologic presentations in unknown primary cancer
    • Nystrom JS, Weiner JM, Heffelfinger-Juttner J (1977) Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 4:53-58
    • (1977) Semin Oncol , vol.4 , pp. 53-58
    • Nystrom, J.S.1    Weiner, J.M.2    Heffelfinger-Juttner, J.3
  • 3
    • 0000149365 scopus 로고    scopus 로고
    • Cancer of unknown primary site
    • Devita VT, Jr, Hellman S, Rosenberg SA (eds). Lippincott-Raven, Philadelphia
    • Greco FA, Hainsworth JD (1997) Cancer of unknown primary site. In: Devita VT, Jr, Hellman S, Rosenberg SA (eds) Principles and practice of oncology, fifth edn. Lippincott-Raven, Philadelphia, pp 2423-2443
    • (1997) Principles and Practice of Oncology, Fifth Edn. , pp. 2423-2443
    • Greco, F.A.1    Hainsworth, J.D.2
  • 4
    • 0023100568 scopus 로고
    • Lack of value for cisplatin added to mitomyin-doxorubicin combination chemotherapy for carcinoma of unknown primary site
    • Eagan RT, Thermean TM, Rubin J (1987) Lack of value for cisplatin added to mitomyin-doxorubicin combination chemotherapy for carcinoma of unknown primary site. Am J Clin Oncol 10:82-85
    • (1987) Am J Clin Oncol , vol.10 , pp. 82-85
    • Eagan, R.T.1    Thermean, T.M.2    Rubin, J.3
  • 6
    • 18544398495 scopus 로고    scopus 로고
    • Docetaxel for the treatment of anthracycline-resistant breast cancer
    • Ravdin PM (1997) Docetaxel for the treatment of nthracycline-resistant breast cancer. Semin Oncol 24(Suppl 1):s10-18-s10-21
    • (1997) Semin Oncol , vol.24 , Issue.SUPPL. 1
    • Ravdin, P.M.1
  • 7
    • 0030051216 scopus 로고    scopus 로고
    • Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer
    • Hudis CA, Seidman AD, Crown JPA, et al. (1996) Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 14:58-65
    • (1996) J Clin Oncol , vol.14 , pp. 58-65
    • Hudis, C.A.1    Seidman, A.D.2    Crown, J.P.A.3
  • 8
    • 0028827482 scopus 로고
    • Phase II trial of docetaxel: A new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
    • Valero V, Holmes FA, Walters RS, et al. (1995) Phase II trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13:2886-2894
    • (1995) J Clin Oncol , vol.13 , pp. 2886-2894
    • Valero, V.1    Holmes, F.A.2    Walters, R.S.3
  • 9
    • 0031427450 scopus 로고    scopus 로고
    • Phase II trials of docetaxel in advanced ovarian cancer: An updated overview
    • Kaye SB, Piccart M, Aapro M (1997) Phase II trials of docetaxel in advanced ovarian cancer: an updated overview. Eur J Cancer 33:2167-2170
    • (1997) Eur J Cancer , vol.33 , pp. 2167-2170
    • Kaye, S.B.1    Piccart, M.2    Aapro, M.3
  • 10
    • 0030461988 scopus 로고    scopus 로고
    • Unknown primary carcinoma: Randomized studies are needed to identify optimal treatments and their benefits
    • Farrugia DC, Norman AR, Nicolson MC, et al. (1996) Unknown primary carcinoma: randomized studies are needed to identify optimal treatments and their benefits. Eur J Cancer 13:2256-2261
    • (1996) Eur J Cancer , vol.13 , pp. 2256-2261
    • Farrugia, D.C.1    Norman, A.R.2    Nicolson, M.C.3
  • 11
    • 0003486931 scopus 로고
    • Offset Publication 48. World Health Organization, Geneva
    • World Health Organization (1979) WHO handbook for reporting results of cancer treatment. Offset Publication 48. World Health Organization, Geneva
    • (1979) WHO Handbook for Reporting Results of Cancer Treatment
  • 12
    • 0032983316 scopus 로고    scopus 로고
    • Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer
    • Vasey PA, Paul J, Birt A, et al. (1999) Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J Clin Oncol 17:2069-2080
    • (1999) J Clin Oncol , vol.17 , pp. 2069-2080
    • Vasey, P.A.1    Paul, J.2    Birt, A.3
  • 13
    • 0031044607 scopus 로고    scopus 로고
    • Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
    • Pank LC, Schellens JHM, Planting AST, et al. (1997) Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 15:1071-1079
    • (1997) J Clin Oncol , vol.15 , pp. 1071-1079
    • Pank, L.C.1    Schellens, J.H.M.2    Planting, A.S.T.3
  • 14
    • 0007548744 scopus 로고    scopus 로고
    • Phase I/II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer
    • Karato A, Hayashi I, Segawa Y, et al. (1997) Phase I/II study of docetaxel and cisplatin in patients with previously untreated metastatic non-small-cell lung cancer, Lung Cancer 18 (Suppl 1):30
    • (1997) Lung Cancer , vol.30 , Issue.SUPPL. 1
    • Karato, A.1    Hayashi, I.2    Segawa, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.